A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with -thalassemia
暂无分享,去创建一个
M. Cappellini | A. Piga | M. Bejaoui | Y. Kilinç | John Porter | A. Kattamis | Y. Aydinok | M. Capra | L. Ağaoğlu | A. Cohen | S. Perrotta
[1] Maya Shvartsman,et al. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. , 2005, Blood.
[2] S. Schrier,et al. New strategies in the treatment of the thalassemias. , 2005, Annual review of medicine.
[3] D. Farmakis,et al. Cardiac status in well‐treated patients with thalassemia major , 2004, European journal of haematology.
[4] A. D. Tsakok. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. , 2004, Blood cells, molecules & diseases.
[5] R. Galanello,et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. , 2003, Blood.
[6] A. Hoffbrand,et al. Role of deferiprone in chelation therapy for transfusional iron overload. , 2003, Blood.
[7] P. Acklin,et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. , 2003, Current medicinal chemistry.
[8] B. Bacon,et al. Iron Toxicity and Chelation Therapy , 2002, International journal of hematology.
[9] G. D’Amico,et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. , 2002, Blood cells, molecules & diseases.
[10] J. Porter. Practical management of iron overload , 2001, British journal of haematology.
[11] G. Link,et al. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. , 2001, Blood.
[12] M. Kami,et al. Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.
[13] R. Fischer,et al. Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry , 1999, American journal of hematology.
[14] G. Lucarelli,et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. , 1997, Blood.
[15] G. Brittenham,et al. Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.
[16] A. Piga,et al. Results of long-term iron-chelating therapy. , 1996, Acta haematologica.
[17] C. McLaren,et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. , 1994, The New England journal of medicine.
[18] J. H. MacMillan,et al. Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.
[19] A. Cohen. Management of iron overload in the pediatric patient. , 1987, Hematology/oncology clinics of North America.
[20] S. Colan,et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. , 1985, The New England journal of medicine.
[21] M. Cubells,et al. Rapid determination of copper, iron, and zinc in liver biopsies , 1984 .
[22] J. Tripp,et al. Magnetic-susceptibility measurement of human iron stores. , 1982, The New England journal of medicine.
[23] Joshua Lederberg,et al. Children's Hospital of Philadelphia. , 1975, The Australasian nurses journal.